Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Melphalan Flufenamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncopeptides Expands WODA Partnership To Africa And Eurasia
    Oncopeptides Expands WODA Partnership To Africa And Eurasia

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940426/0/en/Oncopeptides-expands-on-WODA-partnership-with-addition-of-Africa-and-Eurasia-to-provide-Pepaxti-to-Patients.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Oncopeptides and Vector Pharma Announce Collab to Provide Pepaxti to Patients
    Oncopeptides and Vector Pharma Announce Collab to Provide Pepaxti to Patients

    27 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/27/2853117/0/en/Oncopeptides-and-Vector-Pharma-FZCO-Announce-Collaboration-to-Provide-Pepaxti-to-Patients-in-the-Middle-East-and-North-Africa.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    FDA formally pulls Oncopeptides' cancer drug after prolonged back-and-forth
    FDA formally pulls Oncopeptides' cancer drug after prolonged back-and-forth

    23 Feb 2024

    // ENDPTS

    https://endpts.com/fda-formally-pulls-oncopeptides-cancer-drug-after-prolonged-back-and-forth/

    ENDPTS
    23 Feb 2024
    Share Share
    CDER challenges Oncopeptides’ appeal over Pepaxto withdrawal
    CDER challenges Oncopeptides’ appeal over Pepaxto withdrawal

    13 Sep 2023

    // Lia DeGroot ENDPTS

    https://endpts.com/cder-challenges-oncopeptides-appeal-over-pepaxto-withdrawal/

    Lia DeGroot ENDPTS
    13 Sep 2023
    Share Share
    Oncopeptides provides update on Pepaxto US marketing authorization
    Oncopeptides provides update on Pepaxto US marketing authorization

    07 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/oncopeptides-provides-update-on-pepaxto-us-marketing-authorization-301697069.html

    PRNEWSWIRE
    07 Dec 2022
    Share Share
    Oncopeptides' Pepaxti has been granted marketing authorization in the UK
    Oncopeptides' Pepaxti has been granted marketing authorization in the UK

    11 Nov 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/oncopeptides-pepaxti-has-been-granted-marketing-authorization-in-the-uk-301675786.html

    PRNEWSWIRE
    11 Nov 2022
    Share Share